Benign Prostatic Hyperplasia: What Every Man Should Know About the Enlarged Prostate
If you are a man over 50, there is a reasonable chance your urologist has already mentioned it — or will soon. Benign prostatic hyperplasia, commonly known as BPH or an enlarged prostate, affects more than half of men in their sixties and up to 90% of men in their eighties. Despite being so common, BPH is widely misunderstood, under-discussed, and undertreated. Many men silently tolerate symptoms for years, assuming that slow urine flow or nighttime bathroom trips are simply the price of getting older.
They are not. BPH is a recognized medical condition with well-established diagnostic criteria, a range of evidence-based treatment options, and meaningful consequences if left unaddressed — including urinary tract infections, bladder damage, and in severe cases, acute urinary retention. Understanding what BPH is, how it progresses, and what can be done about it is not just useful — it is essential for any man who wants to maintain quality of life as he ages.
What Is Benign Prostatic Hyperplasia?
The prostate is a walnut-sized gland that sits just below the bladder and surrounds the urethra — the tube through which urine exits the body. Its primary function is to produce seminal fluid. Throughout a man’s life, the prostate undergoes two distinct growth phases: one during puberty and a second that typically begins around age 25 and continues slowly for the rest of a man’s life.
In many men, this second phase of growth eventually becomes significant enough to compress the urethra and obstruct urinary flow. This is benign prostatic hyperplasia — “benign” because it is not cancer, “hyperplasia” because it involves an abnormal increase in the number of cells.
What BPH Is Not
It is worth being explicit: BPH is not prostate cancer, and having BPH does not increase your risk of developing prostate cancer. The two conditions can coexist in the same gland, but they are biologically distinct processes arising from different regions of the prostate. This distinction matters because many men delay seeking evaluation out of fear that symptoms mean cancer, when in fact early assessment and treatment of BPH can prevent serious complications entirely unrelated to malignancy.
Recognizing the Symptoms
BPH produces two categories of urinary symptoms: obstructive (caused by physical blockage of flow) and irritative (caused by bladder changes in response to chronic obstruction). Together, these are called lower urinary tract symptoms, or LUTS.
Obstructive symptoms include:
- Weak or intermittent urine stream
- Difficulty starting urination (hesitancy)
- Straining to urinate
- A sensation that the bladder is not fully emptied
- Dribbling at the end of urination
Irritative symptoms include:
- Frequent urination, especially during the day
- Urgency (a sudden, strong need to urinate)
- Nocturia — waking two or more times at night to urinate
- Urge incontinence in more advanced cases
Symptom severity is typically assessed using the International Prostate Symptom Score (IPSS), a validated 7-question questionnaire that helps clinicians and patients quantify the burden of symptoms and monitor change over time.
How Is BPH Diagnosed?
No single test confirms BPH. Diagnosis is clinical, based on a combination of symptom assessment, physical examination, and selected laboratory or imaging studies.
The Digital Rectal Exam
A urologist can estimate prostate size and texture through a brief digital rectal examination (DRE). An enlarged, smooth, rubbery prostate is consistent with BPH. Firmness, nodularity, or asymmetry may prompt further investigation for prostate cancer.
PSA Testing
Prostate-specific antigen (PSA) is a protein produced by prostate cells. Elevated PSA can reflect BPH, prostatitis, or prostate cancer. In the context of BPH evaluation, PSA can serve as a proxy for prostate volume — larger prostates generally produce more PSA — and can help predict the likelihood of disease progression over time.
Urodynamic Studies and Imaging
In cases where diagnosis is uncertain or surgical planning is required, urodynamic studies (measuring bladder pressure and flow rates) and ultrasound imaging of the prostate may be used. Post-void residual urine measurement — how much urine remains in the bladder after voiding — is another useful parameter, with elevated residuals suggesting significant obstruction.
Treatment Options: From Watchful Waiting to Surgery
The appropriate treatment for BPH depends on symptom severity, prostate size, urinary function, patient preference, and the presence of complications. A structured decision framework helps urologists and patients choose the right approach.
| Treatment Category | Approach | Best For | Limitations |
| Watchful waiting | Active monitoring, lifestyle changes | Mild symptoms (IPSS ≤7) | Not suitable if complications present |
| Alpha-blockers | Tamsulosin, alfuzosin, silodosin | Moderate symptoms, rapid relief | Do not reduce prostate size |
| 5-alpha reductase inhibitors | Finasteride, dutasteride | Large prostate (>30 mL) | Takes 6–12 months for full effect |
| Combination therapy | Alpha-blocker + 5-ARI | Moderate-to-severe symptoms, large prostate | Higher side effect burden |
| Minimally invasive procedures | UroLift, Rezūm, TUMT | Surgery-averse patients | Not all centers offer these options |
| Surgical resection | TURP, HoLEP, open prostatectomy | Severe obstruction, large prostate, complications | Anesthesia and recovery required |
Lifestyle and Behavioral Modifications
Even for patients pursuing pharmacotherapy or surgery, lifestyle changes remain an important adjunct. Recommendations include:
- Reducing fluid intake in the evening to minimize nocturia
- Avoiding caffeine and alcohol, which act as diuretics and bladder irritants
- Practicing double voiding (urinating, waiting a moment, then trying again) to improve bladder emptying
- Avoiding medications that worsen urinary symptoms, such as some antihistamines and decongestants
- Engaging in regular physical activity, which has been associated with lower LUTS severity in observational studies
Alpha-Blockers: The First-Line Pharmacological Choice
Alpha-blockers work by relaxing the smooth muscle in the prostate and bladder neck, reducing urinary resistance. They do not shrink the prostate, but they provide relatively rapid symptom relief — often within days to weeks. Side effects can include dizziness, retrograde ejaculation (semen traveling backward into the bladder rather than out), and orthostatic hypotension, particularly in older men taking antihypertensive medications.
5-Alpha Reductase Inhibitors: Shrinking the Gland
5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT), the primary hormonal driver of prostatic cell growth. By reducing DHT levels in the prostate, finasteride and dutasteride can reduce prostate volume by 20–30% over 12 months, improve urinary flow, and reduce the long-term risk of acute urinary retention and the need for surgery. They are particularly effective in men with larger prostates (>30–40 mL) and elevated PSA.
Surgical Options: When Medication Is Not Enough
When medications fail to adequately control symptoms, when complications arise (urinary retention, recurrent infections, bladder stones, or kidney damage from chronic obstruction), or when the patient prefers a definitive solution, surgery is recommended.
Transurethral Resection of the Prostate (TURP)
TURP has been the gold standard surgical treatment for BPH for decades. A resectoscope is passed through the urethra, and obstructing prostate tissue is removed using electrocautery. No external incision is required. TURP provides excellent long-term symptom relief and is supported by decades of outcome data.
Holmium Laser Enucleation of the Prostate (HoLEP)
HoLEP uses a laser to remove the entire obstructing prostate adenoma from within its capsule, producing outcomes comparable or superior to TURP with less bleeding and shorter catheterization time. It is increasingly adopted in centers with laser surgical expertise, particularly for very large prostates where open surgery was once the only option.
Minimally Invasive Alternatives
Newer technologies like the UroLift system (which mechanically holds open the urethra using implanted sutures) and Rezūm (which uses steam energy to destroy obstructive tissue) offer outpatient procedures with rapid recovery and preservation of sexual function. These are most appropriate for men with moderate symptoms, smaller prostates, and a strong desire to avoid traditional surgery or medication side effects.
Complications of Untreated BPH
Men who dismiss BPH symptoms or delay seeking care face a spectrum of potential complications that extend well beyond inconvenience:
- Acute urinary retention (AUR): A sudden, complete inability to urinate, which constitutes a urological emergency requiring immediate catheterization
- Chronic urinary retention: Gradual accumulation of residual urine, leading to overflow incontinence and kidney damage
- Urinary tract infections (UTIs): Incomplete bladder emptying creates a reservoir for bacterial growth
- Bladder stones: Concentrated stagnant urine promotes stone formation within the bladder
- Bladder dysfunction: Chronic obstruction can permanently alter the bladder muscle (detrusor), reducing contractility and increasing urgency
- Upper tract damage: In severe, longstanding cases, back-pressure from obstruction can cause hydronephrosis and renal impairment
BPH and Quality of Life: The Underappreciated Burden
Clinical measures of BPH — prostate volume, flow rate, post-void residual — are important, but they do not always capture what matters most to patients. Sleep disruption from nocturia is associated with reduced daytime functioning, increased fall risk in older adults, and depression. Anxiety about incontinence affects social engagement and travel. Sexual side effects of some medications — particularly reduced libido and ejaculatory dysfunction — require careful discussion between patient and physician.
The IPSS includes a supplementary quality-of-life question asking how a patient would feel if his current urinary symptoms were to remain the same for the rest of his life. Research consistently shows that patient-reported quality of life is a stronger driver of treatment decisions than objective symptom scores, underscoring the importance of individualized, patient-centered care in BPH management.
Conclusion: Taking Prostate Health Seriously
Benign prostatic hyperplasia is not inevitable, and it is not something men simply have to endure. A wide spectrum of effective treatments exists — from behavioral changes and medication to minimally invasive procedures and surgery — and the right choice depends on the individual patient’s symptoms, prostate characteristics, health status, and preferences.
The key takeaways are straightforward: if you are a man over 50 and experiencing any urinary symptoms, speak to your doctor or urologist. Do not assume slow flow or nighttime voiding are normal aging. Do not assume symptoms mean cancer. And do not wait for complications to develop before seeking evaluation.
Early assessment, accurate diagnosis, and thoughtful management can preserve urinary function, protect kidney health, and dramatically improve quality of life. For evidence-based research and clinical updates on BPH and all aspects of urological health, visit Urology Journal.